Q3 EPS Forecast for Maze Therapeutics Lowered by Analyst

Key Points

• Leerink Partners has lowered its Q3 2025 EPS forecast for Maze Therapeutics to (0.81), compared to the previous estimate of (0.79).
• The company reported quarterly earnings of (0.77) EPS, beating consensus estimates by $0.02, indicating a positive performance despite the lowered forecast.
• Overall, the stock has an average rating of "Buy" with a consensus price target of $25.60, suggesting optimistic expectations from analysts despite recent revisions.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Equities researchers at Leerink Partnrs lowered their Q3 2025 earnings per share (EPS) estimates for Maze Therapeutics in a research report issued on Wednesday, August 13th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of ($0.81) for the quarter, down from their prior forecast of ($0.79). Leerink Partnrs also issued estimates for Maze Therapeutics' Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.54) EPS, Q1 2026 earnings at ($0.82) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.28) EPS and FY2027 earnings at ($2.60) EPS.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.02.

A number of other analysts have also commented on MAZE. Wall Street Zen raised Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright started coverage on Maze Therapeutics in a research note on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price objective on the stock. Finally, Wedbush initiated coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price objective on the stock. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $25.60.

Maze Therapeutics Price Performance

Shares of MAZE stock opened at $13.50 on Monday. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $19.19. The firm has a fifty day moving average price of $13.93.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of MAZE. General Catalyst Group Management LLC purchased a new stake in Maze Therapeutics during the 1st quarter worth approximately $11,405,000. Bessemer Group Inc. purchased a new stake in Maze Therapeutics during the 1st quarter worth approximately $5,305,000. Bank of New York Mellon Corp purchased a new stake in Maze Therapeutics during the 1st quarter worth approximately $190,000. New York State Common Retirement Fund purchased a new stake in Maze Therapeutics during the 1st quarter worth approximately $25,000. Finally, Alphabet Inc. purchased a new stake in Maze Therapeutics during the 1st quarter worth approximately $26,561,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.